Bridging the gap between immunological evidence and national public health decision-making — from the bench to Capitol Hill.
I’ve been a scientist at heart since I was six — the year I got my first microscope and a subscription to Discovery Kids, which I read cover to cover and then started all over again. I grew up in Turkey as the kid who always asked “why?” No one ever managed to talk me out of it.
My family moved to the United States at the end of middle school, and I finished high school in New Jersey, fitting in every science class the schedule would allow. Around the same time, I began volunteering at the Franklin Institute in Philadelphia. That is where I learned something about myself that took me years to fully act on: I love explaining science as much as I love doing it. Watching the moment a concept clicks for someone — regardless of their age, background, or familiarity with the science — is its own kind of result.
After high school, I knew I wanted to pursue a career in research, so I attended the University of the Sciences in Philadelphia, where I earned dual Bachelor of Science degrees in Biochemistry and Bioinformatics. At the same time, I continued working at the Franklin Institute in roles that ranged from developing workshop curricula and presenting live science shows on the museum floor to directing its overnight camp program. Each role taught me how to meet people where they are and make complicated ideas engaging, understandable, and relevant. What began as a high school volunteer position ultimately grew into a relationship with the Franklin Institute that lasted more than twenty years.
Even before beginning my research career, I was drawn to teaching. I taught at Philadelphia University while continuing to develop science curricula, experiences that reinforced my belief that discovering new knowledge and helping others understand it are equally rewarding.
My research career began at Drexel University College of Medicine, where I worked as a laboratory technician studying Legionella pneumophila — biofilm regulation, OmpA-like proteins, and the molecular machinery the pathogen uses to survive inside human cells. During that time, I realized that I needed to continue my formal education, so I pursued a Master of Science in Clinical Infectious Diseases while continuing my laboratory work.
From there, I met neonatologist Alison J. Carey, MD, and joined her newly established neonatal immunology laboratory as its lab manager. As we worked together, we realized that I had the potential to take on a larger and more independent scientific role. I entered graduate school as her first doctoral student, and a new question took hold of me: Why are newborns so immunologically vulnerable?
That question became the focus of my doctoral research. I studied the developmental differences in antiviral immunity that make newborns particularly susceptible to severe respiratory infections, approaching the problem from multiple angles — from cellular and molecular mechanisms to whole-animal models and translational implications. I earned a competitive fellowship that funded my graduate training, was selected for the 2016 NIH Clinical and Translational Research cohort, and received the Amedeo Bondi Award for Excellence in Research and the Dean’s Excellence Award for Collaborative Research.
Graduate school also strengthened something that has shaped every stage of my career: when I see a need, I step forward and act. I became a strong advocate for graduate students, serving as President of the Biomedical Sciences Graduate Student Association, representing students on the Drexel University Graduate Council, and serving on the College of Medicine’s Biomedical Sciences Executive Committee. I brought student concerns directly into the rooms where decisions were made and worked to ensure that graduate student perspectives informed conversations about curriculum, policy, well-being, and the overall training experience.
I took the same approach to leadership in the laboratory, where I trained and mentored master’s students, neonatology fellows, and junior researchers. I did not simply teach techniques; I helped people learn how to think through scientific questions, troubleshoot problems, communicate their work, and become more confident, independent researchers. For me, leadership has never been about holding a title. It is about recognizing what needs to be done, bringing people together, and taking responsibility for moving the work forward.
I chose my postdoctoral fellowship deliberately. I wanted hands-on translational research and a real understanding of how regulators evaluate scientific evidence, and the FDA’s Office of Vaccines Research and Review offered both. There, as part of an NIH-funded cooperative research center, I developed liposome- and outer membrane vesicle-based vaccine candidates against Neisseria gonorrhoeae. My work extended across the preclinical development process, including antigen selection, protein expression and isolation, vaccine formulation, immunization studies, and the evaluation of systemic and mucosal immune responses.
Just as importantly, I gained firsthand insight into how preclinical evidence is judged — through rigorous study design, GLP standards, regulatory documentation, and the frameworks used to assess vaccine safety and immunogenicity. It changes the way you design an experiment when you understand who will evaluate the data next, what questions they will ask, and what evidence they need to make a decision.
That path eventually led me to the National Academies of Sciences, Engineering, and Medicine, where I work on high-stakes evidence reviews commissioned by federal agencies including the CDC, VA, DoD, and FDA. The work brings together experts from many different fields: epidemiology, immunology, clinical medicine, mechanistic biology, public health, statistics, and policy. Each discipline has its own language, standards of evidence, and way of approaching a question.
My role is often to serve as the bridge among experts from these different disciplines. I translate across fields — not by simplifying away the complexity, but by helping people understand how evidence from one area connects to the questions being asked in another. I help bring mechanistic science into conversation with population-level data, clinical experience into conversation with epidemiology, and scientific findings into a form that can inform policy.
That work requires listening closely, recognizing when experts are talking past one another, and asking the questions that move the discussion forward. It also requires helping people with different types of expertise build a shared understanding of what the evidence shows, where it remains uncertain, and what conclusions it can reasonably support.
It is work that draws on every part of my background: the researcher who wants to understand how something works, the educator who has spent decades teaching science in museums, classrooms, and laboratories, and the leader who is willing to step in, connect people, and turn a complicated problem into a path forward.
Taken together, my career has given me an unusually broad view of how biomedical science moves from discovery to public impact — from basic laboratory research and translational development, through regulatory science at the FDA, to evidence synthesis and national health policy. Along the way, I have worked as a researcher, educator, mentor, and scientific leader, and each role has reinforced the same lesson: the strongest scientific decisions rarely come from one type of evidence or one area of expertise. They come from bringing the right people and perspectives together, asking the right questions, and building meaningful connections among them.
The curiosity that started with a childhood microscope is still the engine. The questions have simply gotten bigger — and so has my appreciation that good science is ultimately about improving people’s lives. I still ask “why?” just as often. The difference now is that the answers can help shape research, policy, and the decisions that affect millions of people.
Contributes to comprehensive expert consensus studies on vaccine safety commissioned by the CDC, VA, DoD, and FDA — translating complex immunological evidence into actionable national policy recommendations.
+ ExpandDeveloped liposome- and outer membrane vesicle-based vaccine candidates against Neisseria gonorrhoeae within the FDA's regulatory science framework, evaluating routes and immunogenicity in murine ascending infection models.
+ ExpandExplored whether intranasal Lactobacillus rhamnosus GG administration could rescue neonatal immune defects and restore early viral control during influenza infection — published in PLoS Pathogens.
+ ExpandInvestigated developmental differences in neonatal CD8+ T cells that limit early viral control — from transcriptional reprogramming to clonal dynamics — across murine and human models.
+ ExpandCharacterized the naïve CD8+ T cell receptor repertoire of extremely preterm neonates, demonstrating convergent recombination and public clonotypes — offering insight into why premature infants face heightened infectious risk.
+ ExpandStudied virulence factors and biofilm formation in Legionella pneumophila in the laboratory of Dr. Shira Ninio, characterizing an OmpA-like protein required for efficient intracellular replication.
+ ExpandAs a Program Officer at the National Academies of Sciences, Engineering, and Medicine, I work within the Biomedical and Health Sciences Program Area (BHS) of the Center for Health, People, and Places (CHPP), where I bring expertise in immunology and vaccine science to support expert consensus studies on vaccine safety, monitoring systems, and military and veteran health — commissioned by the CDC, VA, DoD, and FDA. This work bridges scientific evidence and public health decision-making at the highest levels of government.
A National Academies committee is conducting a review of existing systematic reviews to gauge the strength of the evidence base linking six categories of military-service exposure — pesticides, jet fuels, solvents, heavy metals, per- and polyfluoroalkyl substances (PFAS), and fine particulate matter (PM2.5) — to eight neurodegenerative conditions. Each exposure type and its subcategories are examined against each outcome. The committee is not performing new systematic reviews or primary analyses of individual-level data; instead it will recommend where future primary studies or systematic reviews are needed.
View Project →An ad hoc committee of the National Academies is examining the state of scientific evidence on the direct effects of SARS-CoV-2 infection on neurocognitive function across the lifespan — children, adolescents, working-aged adults, and older adults. The committee will also consider implications for military force readiness, military and veteran health, and health system planning.
View Project →An in-depth evaluation of CDC's vaccine safety monitoring systems and infrastructure, assessing current practices and providing recommendations to strengthen national vaccine risk surveillance.
View Report →A comprehensive evidence review examining adverse effects associated with COVID-19 vaccines and intramuscular vaccine administration, produced for federal health agencies to inform vaccine safety policy.
View Report →Prepared an invited briefing on Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention for Congressional staff of the U.S. House and Senate Appropriations Committees and the Senate HELP Committee.
Prepared an invited briefing on COVID-19 vaccine safety for Congressional staff of the U.S. House and Senate Appropriations Committees and the Senate HELP Committee.
Teaching has been part of my life since long before I was formally a teacher. It started at the Franklin Institute in Philadelphia, where I walked in as a high school volunteer and ended up staying for more than twenty years. I did nearly every job the floor had: live science shows and demonstrations for the public, workshops built for visiting school groups, and eventually the overnight camp-in program — which I managed and then directed for a season, shepherding several hundred kids and their very tired chaperones through a museum after dark. It was the best informal-education training I could have asked for. You learn quickly how to read a room, how to find the version of an explanation that lands for a six-year-old and the version that lands for their skeptical parent, and that if you can't connect science to something a person already cares about, it doesn't stick. I still teach that way.
I teach science as a process of discovery rather than a collection of facts to memorize. In my classroom, I want students to understand not only what is happening, but why — and how they can work through it themselves. I rely on guided discussion, Socratic questioning, collaborative activities, and real-world case studies. I also deliberately avoid anchoring my courses to a single textbook — drawing instead from primary literature, case studies, and open educational resources. As zero-cost course initiatives like Z-courses and OER adoption become more widespread, I believe removing textbook barriers is one of the most practical ways faculty can support equitable access to education.
My teaching has spanned a wide range of learners — community college students returning to school after years away, undergraduates entering health professions, graduate and medical students, postdoctoral fellows, and neonatology fellows. At Rowan College at Burlington County, I run the Health and Human Microbiology course for health-profession students and also teach Biology I, Biology II, and Basic Microbiology. At Drexel University College of Medicine and Uniformed Services University, I lecture in microbiology, immunology, molecular pathogenesis, and vaccine development.
Good teaching is not about simplifying material until it loses its depth. It's about presenting it with clarity, structure, and relevance — and making sure students feel supported enough to engage actively with challenging ideas.
Myeloid TLR2 signaling amplifies immunopathology in influenza-infected murine neonates.
Vaccine Risk Monitoring and Evaluation at the Centers for Disease Control and Prevention.
Severity of neonatal influenza infection is driven by type I interferon and oxidative stress.
Characterization of a novel regulator of biofilm formation in the pathogen Legionella pneumophila.
Dissecting the defects in the neonatal CD8+ T-cell response.
Rapid Evolution of the CD8+ TCR Repertoire in Neonatal Mice.
A full academic CV and targeted resumes for academic, government, and industry roles are available below.
I'm always happy to connect with colleagues, collaborators, and anyone interested in vaccine science, immunology, or science policy. I welcome conversations about collaboration, shared interests, and new directions.